Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00510302 · ClinicalTrials.gov registry record
Melanoma Risk-Reduction Among Patients and Family Members
A clinical trial of Melanoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 170
- Enrollment target
- 1
- Study location
NCT00510302 is a study of Melanoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 170 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00510302, a study of Melanoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objectives: * To conduct semi-structured interviews with melanoma patients and family members to collect descriptive information on their UVR exposure, UVR exposure-reduction practices, melanoma early detection practices, knowledge, psychosocial variables related to melanoma risk-reduction (e.g., self-efficacy, norms, and expectations), and experiences surrounding the diagnosis of melanoma in the family. Melanoma patients and family members with children will be asked about the UVR exposure and UVR exposure-reduction practices of their children, and parental practices to reduce UVR exposure among children. * To develop behavioral and attitudinal questionnaires based on data collected during semi-structured interviews, and evaluate the appropriateness of these questionnaires using cognitive interviewing techniques. * To develop tailored messages aimed at promoting strategies to reduce UVR exposure (e.g., wearing protective clothing, minimizing midday UVR exposure, minimizing duration of UVR exposure, using shade and sunscreen, avoiding sun lamps, and avoiding intentional tanning) and improving adherence to surveillance and screening guidelines. Messages will be developed to correspond to responses to questionnaire items. * To assess tailored messages for their relevance, appropriateness, attractiveness and appeal, credibility, and perceived behavioral impact among melanoma patients and their family members.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaire
- BEHAVIORAL Interview
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2002-11-18 |
| Est. Completion | 2020-09-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00510302
The ClinicalTrials.gov registry entry for NCT00510302 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (76% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire is the first listed.
NCT00510302 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00510302 about?
NCT00510302 is a clinical study titled "Melanoma Risk-Reduction Among Patients and Family Members". Primary Objectives: * To conduct semi-structured interviews with melanoma patients and family members to collect descriptive information on their UVR exposure, UVR exposure-reduction practices, melanoma early detection practices, knowledge, psychosocial variables related to melanoma risk-reduction ...
What is the current status of trial NCT00510302?
This trial is currently completed. The enrollment target is 170 participants. The study started on 2002-11-18. Estimated completion is 2020-09-14.
What conditions does trial NCT00510302 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00510302?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Interview (BEHAVIORAL).
Who is sponsoring clinical trial NCT00510302?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00510302 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.